News flow28 May 2020 11:40
Leeds, 11 May 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group" or "Company"), a leading regenerative medicine company, is pleased to announce that it has entered a new strategic collaboration for white label manufacturing with a leading top 10 global healthcare company bringing to market a newly developed product line.
The manufacturing agreement follows collaboration between the R&D teams of both companies to develop a new product using one of the Group's proprietary technology platforms to address orthopaedic soft tissue repairs. Processing for the product has begun, and initial orders have been received. Over the next two years, it is expected that the product will make a material contribution to the Group's top line revenue growth. This new product line is complimentary to the other soft tissue products processed at the San Antonio facility, and due to operational efficiencies implemented, it is not expected that there will be any impact on the current processing levels of other product lines.